62
edits
Changes
→References
==References==
==References==
1. Jennings, G. T. et al. Cytosolic NADP (+)-dependent isocitrate dehydrogenase. Isolation of rat cDNA and study of tissue-specific and developmental expression of mRNA. J. Biol. Chem. 269, 23128–23134 (1994). PMID: 8083215
2. Yoshihara, T. et al. Localization of Cytosolic NADP-dependent Isocitrate Dehydrogenase in the Peroxisomes of Rat Liver Cells: Biochemical and Immunocytochemical Studies. J. Histochem. Cytochem. 49, 1123–1131 (2001). PMID: 11511681
3. Xu, X. et al. Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of Activity. J. Biol. Chem. 279, 33946–33957 (2004). PMID: 15173171
4. Zhao, S. et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324, 261–265 (2009). PMID: 19359588
5. Khurshed, M., Molenaar, R. J., Lenting, K., Leenders, W. P. & van Noorden, C. J. F. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma. Oncotarget 8, (2017). PMID: 28467784
6. Bleeker, F. E. et al. The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. (Berl.) 119, 487–494 (2010). PMID: 20127344
7. Minard, K. I. & McAlister-Henn, L. Dependence of peroxisomal β-oxidation on cytosolic sources of NADPH. J. Biol. Chem. 274, 3402–3406 (1999). PMID: 9920883
8. Mailloux, R. J. et al. The Tricarboxylic Acid Cycle, an Ancient Metabolic Network with a Novel Twist. PLoS ONE 2, e690 (2007). PMID: 17668068
9. Lee, S. M. et al. Cytosolic NADP+-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic. Biol. Med. 32, 1185–1196 (2002). PMID: 12031902
10. Yang, E. S., Lee, S.-M. & Park, J.-W. Silencing of cytosolic NADP+-dependent isocitrate dehydrogenase gene enhances ethanol-induced toxicity in HepG2 cells. Arch. Pharm. Res. 33, 1065–1071 (2010). PMID: 20661717
11. Lee, S. ‐H. et al. Role of NADP + ‐dependent isocitrate dehydrogenase (NADP + ‐ICDH) on cellular defence against oxidative injury by γ ‐rays. Int. J. Radiat. Biol. 80, 635–642 (2004). PMID: 15586883
12. Jo, S.-H. et al. Cellular defense against UVB-induced phototoxicity by cytosolic NADP+-dependent isocitrate dehydrogenase. Biochem. Biophys. Res. Commun. 292, 542–549 (2002). PMID: 11906195
13. Lee, S. M., Huh, T.-L. & Park, J.-W. Inactivation of NADP+-dependent isocitrate dehydrogenase by reactive oxygen species. Biochimie 83, 1057–1065 (2001). PMID: 11879734
14. Batinic-Haberle, I. & Benov, L. T. An SOD mimic protects NADP + -dependent isocitrate dehydrogenase against oxidative inactivation. Free Radic. Res. 42, 618–624 (2008). PMID: 18608518
15. Shechter, I., Dai, P., Huo, L. & Guan, G. IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells. J. Lipid Res. 44, 2169–2180 (2003). PMID: 12923220
16. Joseph, J. W. et al. The Mitochondrial Citrate/Isocitrate Carrier Plays a Regulatory Role in Glucose-stimulated Insulin Secretion. J. Biol. Chem. 281, 35624–35632 (2006). PMID: 17001083
17. Koh, H.-J. et al. Cytosolic NADP + -dependent Isocitrate Dehydrogenase Plays a Key Role in Lipid Metabolism. J. Biol. Chem. 279, 39968–39974 (2004). PMID: 15254034
18. Ronnebaum, S. M. et al. A Pyruvate Cycling Pathway Involving Cytosolic NADP-dependent Isocitrate Dehydrogenase Regulates Glucose-stimulated Insulin Secretion. J. Biol. Chem. 281, 30593–30602 (2006). PMID: 16912049
19. Reitman, Z. J. & Yan, H. Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism. JNCI J. Natl. Cancer Inst. 102, 932–941 (2010). PMID: 20513808
20. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009). PMID: 23532369
21. Sanson, M. et al. Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas. J. Clin. Oncol. 27, 4150–4154 (2009). PMID: 19636000
22. Nobusawa, S., Watanabe, T., Kleihues, P. & Ohgaki, H. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clin. Cancer Res. 15, 6002–6007 (2009). PMID: 19755387
23. Lugowska, I. et al. IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma. J. Cancer 9, 998–1005 (2018). PMID: 29581779
24. Amary, M. F. et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 224, 334–343 (2011). PMID: 21598255
25. Pansuriya, T. C. et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat. Genet. 43, 1256–1261 (2011). PMID: 22057234
26. Wang, P. et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32, 3091–3100 (2013). PMID: 22824796
27. Borger, D. R. et al. Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. The Oncologist 17, 72–79 (2012). PMID: 22180306
28. Churi, C. R. et al. Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications. PLOS ONE 9, e115383 (2014). PMID: 25536104
29. Goyal, L. et al. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. The Oncologist 20, 1019–1027 (2015). PMID: 26245674
30. Jiao, Y. et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 45, 1470–1473 (2013). PMID: 24185509
31. Mardis, E. R. et al. Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome. N. Engl. J. Med. 361, 1058–1066 (2009). PMID: 19657110
32. Xu, Q. et al. Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Clin. Cancer Res. 23, 4511–4522 (2017). PMID: 28246275
33. Schnittger, S. et al. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 116, 5486–5496 (2010). PMID: 20805365
34. Patnaik, M. M. et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients. Leukemia 26, 101–105 (2012). PMID: 22033490
35. Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324 (2014). PMID: 25043048
36. Farshidfar, F. et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 18, 2780–2794 (2017). PMID: 28658632
37. Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209–2221 (2016). PMID: 27276561
38. Molenaar, R. J. et al. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia 29, 2134 (2015). PMID: 25836588
39. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009). PMID: 19935646
40. Molenaar, R. J., Maciejewski, J. P., Wilmink, J. W. & van Noorden, C. J. F. Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene 37, 1949–1960 (2018). PMID: 29367755
41. Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891–899 (2004). PMID: 15516961
42. Frezza, C., Tennant, D. A. & Gottlieb, E. IDH1 Mutations in Gliomas: When an Enzyme Loses Its Grip. Cancer Cell 17, 7–9 (2010). PMID: 20129244
43. Chan, S. M. et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21, 178–184 (2015). PMID: 25599133
44. Karpel-Massler, G. et al. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. Nat. Commun. 8, (2017). PMID: 29057925
45. Tateishi, K. et al. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell 28, 773–784 (2015). PMID: 26678339
46. Chen, F. et al. Oncometabolites D - and L -2-Hydroxyglutarate Inhibit the AlkB Family DNA Repair Enzymes under Physiological Conditions. Chem. Res. Toxicol. 30, 1102–1110 (2017). PMID: 28269980
47. Sulkowski, P. L. et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci. Transl. Med. 9, eaal2463 (2017). PMID: 28148839
48. Inoue, S. et al. Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. Cancer Cell 30, 337–348 (2016). PMID: 27424808
49. Noushmehr, H. et al. Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell 17, 510–522 (2010). PMID: 20399149
50. Figueroa, M. E. et al. Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell 18, 553–567 (2010). PMID: 21130701
51. Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479–483 (2012). PMID: 22343889
52. Losman, J.-A. & Kaelin, W. G. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27, 836–852 (2013). PMID: 23630074
53. Tönjes, M. et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat. Med. 19, 901–908 (2013). PMID: 23793099
54. Molenaar, R. J. et al. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Res. 75, 4790–4802 (2015). PMID: 26363012
55. Shi, J. et al. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. Tumor Biol. 36, 655–662 (2015). PMID: 25283382
56. Molenaar, R. J., Radivoyevitch, T., Maciejewski, J. P., van Noorden, C. J. & Bleeker, F. E. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim. Biophys. Acta BBA-Rev. Cancer 1846, 326–341 (2014). PMID: 24880135
57. Gilbert, M. R. et al. Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol. (Berl.) 127, 221–233 (2014). PMID: 24150401
58. Ohgaki, H. & Kleihues, P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 100, 2235–2241 (2009). PMID: 19737147
59. Watanabe, T., Nobusawa, S., Kleihues, P. & Ohgaki, H. IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas. Am. J. Pathol. 174, 1149–1153 (2009). PMID: 19246647
60. Watanabe, T., Vital, A., Nobusawa, S., Kleihues, P. & Ohgaki, H. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol. (Berl.) 117, 653–656 (2009). PMID: 19340432
61. The Cancer Genome Atlas Research Network. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med. 372, 2481–2498 (2015). PMID: 26061751
62. Chou, W.-C. et al. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 25, 246–253 (2011). PMID: 21079611
63. Marcucci, G. et al. IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J. Clin. Oncol. 28, 2348–2355 (2010). PMID: 20368543
64. Feng, J.-H. et al. Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. Am. J. Blood Res. 2, 254 (2012). PMID: 23226625
65. Cuyàs, E. et al. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget 6, (2015). PMID: 25980580
66. Molenaar, R. J. et al. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1 -mutated or IDH2 -mutated solid tumours. BMJ Open 7, e014961 (2017). PMID: 28601826
67. Seltzer, M. J. et al. Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1. Cancer Res. 70, 8981–8987 (2010). PMID: 21045145
68. Elhammali, A. et al. A High-Throughput Fluorimetric Assay for 2-Hydroxyglutarate Identifies Zaprinast as a Glutaminase Inhibitor. Cancer Discov. 4, 828–839 (2014). PMID: 24740997
69. Emadi, A. et al. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp. Hematol. 42, 247–251 (2014). PMID: 24333121
70. Mohrenz, I. V. et al. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis 18, 1416–1425 (2013). PMID: 23801081
71. Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380–384 (2012). PMID: 22101433
72. Calvert, A. E. et al. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. Cell Rep. 19, 1858–1873 (2017). PMID: 28564604
73. Konopleva, M. et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 6, 1106–1117 (2016). PMID: 27520294
74. Saha, S. K. et al. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discov. 6, 727–739 (2016). PMID: 27231123
75. Boutzen, H. et al. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J. Exp. Med. 213, 483–497 (2016). PMID: 26951332
76. Zarei, M. et al. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Cancer Res. 77, 4460–4471 (2017). PMID: 28652247
77. Kim, S. Y., Yoo, Y. H. & Park, J.-W. Silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase gene enhances glioma radiosensitivity. Biochem. Biophys. Res. Commun. 433, 260–265 (2013). PMID: 23500467
78. Wang, J.-B., Dong, D.-F., Wang, M.-D. & Gao, K. IDH1 Overexpression Induced Chemotherapy Resistance and IDH1 Mutation Enhanced Chemotherapy Sensitivity in Glioma Cells in Vitro and in Vivo. Asian Pac. J. Cancer Prev. 15, 427–432 (2014). PMID: 24528069
79. Wang, P. et al. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Rep. 13, 2353–2361 (2015). PMID: 26686626
80. Buckner, J. C. et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N. Engl. J. Med. 374, 1344–1355 (2016). PMID: 27050206
81. SongTao, Q. et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 103, 269–273 (2012). PMID: 22034964
82. Molenaar, R. J. et al. IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. Clin. Cancer Res. 24, 1705–1715 (2018). PMID: 29339439
83. Lu, Y. et al. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. Cancer Res. 77, 1709–1718 (2017). PMID: 28202508
84. Popovici-Muller, J. et al. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med. Chem. Lett. 3, 850–855 (2012). PMID: 24900389
85. Popovici-Muller, J. et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Med. Chem. Lett. 9, 300–305 (2018). PMID: 29670690
86. Rohle, D. et al. An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. Science 340, 626–630 (2013). PMID: 23558169
87. Li, L. et al. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. PLOS ONE 10, e0133813 (2015). PMID: 26368816
88. Birendra, K. C. & DiNardo, C. D. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. Clin. Lymphoma Myeloma Leuk. 16, 460–465 (2016). PMID: 27245312
== Notes ==
== Notes ==